Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Zheng bo Song"'
Autor:
You-cai Zhu, Wen-xian Wang, Chun-wei Xu, Wu Zhuang, Zheng-bo Song, Kai-qi Du, Gang Chen, Tang-feng Lv, Yong Song
Publikováno v:
Cancer Biology & Therapy, Vol 19, Iss 12, Pp 1097-1101 (2018)
In non-small cell lung cancer (NSCLC), driver gene alterations, such as EGFR, ALK, MET, and ROS1, are usually mutually exclusive. Few clinical cases with co-existing ROS1 fusion and de-novo MET amplification have been reported. In addition, the effic
Externí odkaz:
https://doaj.org/article/9b7ae0f932f24e0aa83d261b00db2d57
Publikováno v:
Strahlentherapie und Onkologie. 199:313-321
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4195909eb4456cc67c4d43d7db987df8
https://doi.org/10.1007/s00066-022-02042-w
https://doi.org/10.1007/s00066-022-02042-w
Autor:
Chun-wei Xu, Wen-xian Wang, Yan-ping Chen, Yu Chen, Wei Liu, Li-hua Zhong, Fang-fang Chen, Wu Zhuang, Zheng-bo Song, Xiao-hui Chen, Yun-jian Huang, Yan-fang Guan, Xin Yi, Tang-feng Lv, Wei-feng Zhu, Jian-ping Lu, Xiao-jiang Wang, Yi Shi, Xian-dong Lin, Gang Chen, Yong Song
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-10 (2018)
Abstract Background ALK rearrangement-advanced NSCLC patients respond to crizotinib. ALK rearrangement is currently determined with RT-PCR. VENTANA IHC is a standard method to identify ALK protein overexpression in NSCLC; however, VENTANA IHC has rar
Externí odkaz:
https://doaj.org/article/670ffea6efa64531975757d75f66d41a
Autor:
Jia-Nan Jin, Peng Yue, Yue Hao, Shi-Yan Wu, Bai-Qiang Dong, Qing Wu, Zheng-Bo Song, Ming Chen
Publikováno v:
Medicine. 101(46)
Oligometastatic non-small-cell lung cancer (NSCLC) is potentially curable. Oligo-recurrence occurs with oligometastatic disease characterized by well-controlled primary lesion. The purpose of the present study was to explore the value of definitive l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ea5324b1b03fb4c56785ed6926cee9d
https://pubmed.ncbi.nlm.nih.gov/36401441
https://pubmed.ncbi.nlm.nih.gov/36401441
Autor:
Jing-Wen Wei, Yue Hao, Jing Xiang, Xing-Xiang Pu, Li-Ping Wang, Zhan-Sheng Jiang, Jing-Xun Wu, Qian Wang, Chun-Wei Xu, Wen-Xian Wang, Zheng-Bo Song
Publikováno v:
Neoplasma. 69(6)
Pulmonary sarcomatoid carcinoma (PSC) is an aggressive and poorly differentiated type of non-small cell lung carcinoma. Because of the rarity of PSC, the efficacy and toxicity of immunotherapy remain unclear. Hence, the aim of this study was to evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef71528e9d0ad0719b86dfe39e37a37a
https://pubmed.ncbi.nlm.nih.gov/36353935
https://pubmed.ncbi.nlm.nih.gov/36353935
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 29, Iss 12, Pp 662-666 (2013)
Preoperative elevation of serum C-reactive protein (CRP) is reportedly associated with poor prognosis in several types of cancer. This study investigated the role of serum CRP as a prognostic factor in early-stage esophageal squamous cell carcinoma (
Externí odkaz:
https://doaj.org/article/8418a207923c4752b31389fa1403cf7c
Autor:
Na Liu, Bi-Lin Liang, Lu Lu, Bing-Qian Zhang, Jing-Jing Sun, Jian-Tao Yang, Jie Xu, Zheng-Bo Song, Lei Shi
Background Immunotherapy has improved the prognosis of patients with advanced non-small cell lung cancer (NSCLC), but only a small subset of patients achieved clinical benefit. The purpose of our study was to integrate multidimensional data using a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e466f1bcf76ef59ec82ee401d876c4
https://doi.org/10.21203/rs.3.rs-1688580/v1
https://doi.org/10.21203/rs.3.rs-1688580/v1
Publikováno v:
Neoplasma. 69(4)
We aimed to explore the treatment efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung squamous cell carcinoma (SCC) patients and identify potential beneficial subgroups of EGFR-mutated lung SCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec0cb071f03bd511d855814394b6e5a
https://pubmed.ncbi.nlm.nih.gov/35603955
https://pubmed.ncbi.nlm.nih.gov/35603955
Autor:
Na LIU, Bi-Lin LIANG, Lu LU, Bing-Qian ZHANG, Jing-Jing SUN, Jian-Tao YANG, Jie XU, Zheng-Bo SONG, Lei SHI
Publikováno v:
Neoplasma; 2023, Vol. 70 Issue 2, p300-310, 13p
Autor:
Xinghao Ai, Ziming Li, Zhiwei Chen, Hong Jian, Zhen Zhou, Zheng-bo Song, Shun Lu, Yongfeng Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Background Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), anti-HER2 antibody drug conjug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541e6c7beda54a6449217a9a15607392
http://europepmc.org/articles/PMC8444597
http://europepmc.org/articles/PMC8444597